Keith Orford

Director/Board Member at CALITHERA BIOSCIENCES, INC.

Net worth: 1 $ as of 31/05/2024

52 year

Health Technology

Consumer Services

Profile

Dr. Keith Orford is a Chief Medical Officer & Executive VP-Clinical at Fog Pharmaceuticals, Inc. He is on the Board of Directors at Calithera Biosciences, Inc. Dr. Orford was previously employed as a Clinical Development Lead-Immuno-Oncology by GlaxoSmithKline Plc.
He received his doctorate degree from Georgetown University.

Known holdings in public companies

Company	Date	Number of shares	Valuation	Valuation date
CALITHERA BIOSCIENCES, INC. 0.00%	30/04/2023	54 ( 0.00% )	1 $	31/05/2024

Keith Orford active positions

Companies	Position	Start
CALITHERA BIOSCIENCES, INC.	Director/Board Member	05/11/2021
Fog Pharmaceuticals, Inc. Fog Pharmaceuticals, Inc. BiotechnologyHealth Technology Fog Pharmaceuticals, Inc. develops pharmaceutical products. It discovers and develops cell-penetrating miniproteins (CPMPs), which are specifically designed to target cancer-causing proteins inside cancer cells and neutralize them. The company was founded by Gregory L. Verdine, WeiQing Zhou and David Philip Lane and is headquartered in Cambridge, MA.	Chief Tech/Sci/R&D Officer	01/11/2021

All active positions of Keith Orford

Former positions of Keith Orford

Companies	Position	End
GSK PLC	Corporate Officer/Principal	01/01/2015

See the detail of Keith Orford's experience

Training of Keith Orford

Georgetown University

Doctorate Degree

Experiences
Positions held

Active

Inactive

Listed companies

Private companies

See the detail of Keith Orford's experience

Connections

100 +

1st degree connections

1st degree companies

Male

Female

Members of the board

Executives

See the personal network

Linked companies

Listed companies	2
CALITHERA BIOSCIENCES, INC.	Health Technology
GSK PLC	Health Technology

Private companies	1
Fog Pharmaceuticals, Inc. Fog Pharmaceuticals, Inc. BiotechnologyHealth Technology Fog Pharmaceuticals, Inc. develops pharmaceutical products. It discovers and develops cell-penetrating miniproteins (CPMPs), which are specifically designed to target cancer-causing proteins inside cancer cells and neutralize them. The company was founded by Gregory L. Verdine, WeiQing Zhou and David Philip Lane and is headquartered in Cambridge, MA.	Health Technology